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Treatment of the primary 
hyperoxalurias: A new chapter
D Milliner1
Despite advances in the enzymology, molecular genetics, and clinical 
knowledge of the primary hyperoxalurias, few treatments are available. 
Oxalobacter formigenes is a promising new therapy with potential to 
induce secretion of oxalate into the intestinal lumen, where it can be 
degraded by the bacteria.
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Progress in understanding of the primary 
hyperoxalurias has been notable.1 Aft er 
early clinical descriptions of the disease 
by several authors and recognition of its 
heredity, defi ciencies of specifi c hepatic 
enzymes important in glyoxylate metabo-
lism were confi rmed in the 1980s as the 
cause of marked overproduction of oxalate 
in primary hyperoxaluria type 1 and type 
2. Enzyme phenotypes have since been 
described, including a unique intracellular 
protein traffi  cking defect in type 1 disease 
in which alanine:glyoxylate aminotrans-
ferase (AGT) is mistargeted from its usual 
location in the peroxisomes to the mito-
chondria, where it is metabolically inac-
tive.1 Characterization of the genes coding 
for these enzymes in the 1990s was fol-
lowed in 2003 by resolution of the crystal 
structure of AGT. Th e locations and pos-
sible conformational eff ects of common 
mutations found in primary hyperoxaluria 
type 1 have been described.2
 Albeit less complete, an appreciation of 
the physiology of oxalate has come about in 
parallel. Oxalate is an end product of hepa-
tocyte disposition of glyoxylate and is not 
able to be metabolized by mammalian cells. 
Once it is produced by the liver or absorbed 
from the diet, elimination from the body is 
required to maintain physiologic balance. 
Th e kidney is capable of net reabsorption 
or secretion of oxalate and is the primary 
route of elimination of oxalate. Th e impor-
tance of the gastrointestinal tract in oxalate 
homeostasis has been demonstrated, and 
regulatory factors have been identifi ed.3 
Bidirectional transport of oxalate has been 
demonstrated in proximal renal tubules 
and intestinal epithelia. Recent evidence 
suggests a role of the Slc26a6 gene in both 
renal and enteric oxalate transport.4,5 Yet 
despite this advancing knowledge, treat-
ment for patients with primary hyper-
oxaluria has remained largely unchanged 
for more than two decades.
Primary hyperoxaluria types 1 and 2 
are autosomal recessive inborn errors 
of metabolism in which deficiency of 
the hepatic enzyme alanine:glyoxylate 
aminotransferase (AGT) or glyoxylate/
hydroxypyruvate reductase (GR/HPR), 
respectively, results in marked hepatic 
overproduction of oxalate. Patients with 
similar clinical fi ndings, but with normal 
activity of hepatic AGT and GR/HPR, 
have also been described. The specific 
cause(s) of these other forms of primary 
hyperoxaluria is as yet unknown. For-
mation of calcium oxalate stones in the 
urinary tract, nephrocalcinosis, and, over 
time, irreversible renal injury are the 
hallmarks of the disease, though variable 
in their expression. For example, some 
patients present in infancy with end-stage 
renal failure, whereas others have well-
preserved renal function into their sixth 
or seventh decade of life. Data from the 
International Registry for Primary Hyper-
oxaluria show a steady renal attrition rate 
from the second to the sixth decade of life 
among patients with type 1 disease.6
Th e cause of the renal injury is the sub-
ject of active investigation. Damage may be 
due to direct cell toxicity of high concentra-
tions of oxalate, though increasing infor-
mation suggests that it is calcium oxalate 
crystals that are injurious. Calcium oxalate 
crystals form in the lumen of renal tubules, 
adhere to tubular epithelium, and are inter-
nalized into cells. Th e crystals appear to 
traverse the cell and are then extruded into 
interstitial regions of the kidney, where an 
infl ammatory reaction ensues. Evidence to 
date implicates reactive oxygen species and 
infl ammatory mediators of injury leading 
to fi brosis.7 Over time, there is irreversible 
loss of renal function.
Th e degree of hyperoxaluria is a factor 
in the severity of renal injury. Among 115 
patients enrolled in the International Reg-
istry for Primary Hyperoxaluria, 68 had 
urine oxalate measurements prior to renal 
failure. Th ose with urine oxalate excretion 
rates less than the median of the group had 
signifi cantly better 20-year renal survival 
from diagnosis (92%) as compared with 
those with urine oxalate excretion rates 
greater than the median (72%, P = 0.018) 
(Figure 1). Th us, measures that reduce 
urine oxalate would be expected to be of 
therapeutic benefi t.
Pharmacologic doses of pyridoxine, 
when administered to patients with pri-
mary hyperoxaluria type 1, reduce urine 
oxalate, but only in patients with specifi c 
genotypes.8 Th us pyridoxine benefi ts the 
approximately 30%–50% of type 1 patients 
who are homozygous or heterozygous for 
these alleles but is not eff ective in other 
forms of the disease. Th e eff ect of pyri-
doxine is thought to be related to its role as 
a cofactor for AGT, but the specifi c mech-
anism of action is still unknown despite 
recognition of its effi  cacy and clinical use 
since before 1970. 
Liver transplantation has been the only 
other modality available to reduce urine 
oxalate excretion and has been demon-
strated to correct the metabolic defect in 
type 1 disease, but it has not been tested 
in other forms of primary hyperoxaluria. 
Defi cient AGT enzyme can be replaced 
by whole-liver transplantation, but only 
at the expense of surgical removal of the 
patient’s otherwise healthy liver and a 
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lifetime of immune suppression. Eff orts 
to restore enzyme activity by hepatocel-
lular transplantation or molecular thera-
peutics are in their infancy. A variety 
of previous efforts to reduce synthesis 
of oxalate in primary hyperoxaluria by 
manipulation of glyoxylate metabolism 
have been unsuccessful. Treatment is oth-
erwise limited to high fl uid intake to keep 
oxalate concentrations in the urine as low 
as possible, inhibitors of calcium oxalate 
crystallization that must be administered 
several times per day, and attentive man-
agement of urinary tract stones. Th e loss 
of renal function that is so oft en observed 
in patients with primary hyperoxaluria 
despite these eff orts speaks to the urgent 
need for more eff ective treatments.
Th e kidney eliminates oxalate effi  ciently. 
As long as there is suffi  cient renal function 
to excrete the large amount of oxalate pro-
duced, plasma oxalate concentrations are 
only mildly elevated and injury is largely 
confined to the kidneys. However, the 
problem of excess oxalate is acute for pri-
mary hyperoxaluria patients in stage 4 or 
stage 5 renal failure, whose plasma oxalate 
concentrations are markedly elevated. 
When the saturation threshold for calcium 
oxalate in the blood is exceeded, systemic 
deposition of calcium oxalate is the result, 
with devastating multisystem organ dys-
function and, in some cases, death. With 
conventional dialysis, removal of oxalate 
does not keep pace with daily production 
in patients with primary hyperoxaluria, 
and this leaves them at risk of systemic 
oxalate accumulation (oxalosis) while 
they await transplantation.
In recent years the role of the intestinal 
tract in handling of oxalate has begun to 
be understood, including early insights 
into physiologic regulation of enteric 
oxalate transport.3 Th e appreciation of 
oxalate absorption and secretion by seg-
ments of the intestine under regulatory 
control has opened the door for pharma-
cologic manipulation of oxalate excretion 
by the intestinal tract.
A number of intestinal bacteria have 
been found to degrade oxalate, including 
Oxalobacter formigenes.3 Th ere is sugges-
tive evidence in both laboratory animals 
and humans with stone disease that enteric 
colonization by Oxalobacter infl uences the 
amount of oxalate excreted in the urine by 
degradation of intestinal oxalate derived 
from dietary sources, and thus prevention 
of its absorption. Applicability of these 
observations to patients with primary 
hyperoxaluria at fi rst seemed limited, as 
the source of the marked hyperoxaluria in 
this disease is the liver, with only a small 
fraction of the urinary oxalate derived 
from dietary oxalate intake. Th en in 2006, 
Hatch et al. demonstrated that, in addi-
tion to its intraluminal oxalate-degrading 
activity, Oxalobacter colonization was able 
to induce colonic secretion/excretion of 
endogenously produced oxalate in a rat 
model.9 As a result of enhanced enteric 
secretion, urine oxalate was reduced.
Hoppe and colleagues10 (this issue) 
report the eff ect of oral administration 
of O. formigenes to patients with primary 
hyperoxaluria type 1. Th e decline in urine 
and plasma oxalate observed during treat-
ment appears to provide clinical verifi ca-
tion of the studies of Hatch et al.9 The 
benefi t seen in patients with normal renal 
function, aft er end-stage renal failure dur-
ing dialysis, and aft er transplantation is in 
keeping with the mechanisms proposed. 
Th e data suggest applicability of this treat-
ment to primary hyperoxaluria patients 
at all stages of their disease. Of particular 
interest is the prospect of enhanced enteric 
secretion of oxalate in patients who are in 
renal failure and on maintenance dialysis.
Th e eff ect on urine and plasma oxalate 
was quite variable from patient to patient. 
Some showed only modest improvement 
following Oxalobacter administration. 
The authors’ observations10 regarding 
the eff ect of Oxalobacter require verifi -
cation in larger numbers of patients. An 
understanding of the factors infl uencing 
individual variability in response and an 
assessment of longer-term clinical benefi t 
will be important. If the results are con-
fi rmed, Oxalobacter should be useful in all 
types of primary hyperoxaluria and may 
be fruitful for study in enteric and other 
forms of hyperoxaluria as well.
Th e work of Hoppe and colleagues,10 
using oral administration of Oxalobacter 
to induce secretion of oxalate by the intes-
tinal tract into the lumen, where it can be 
degraded by the bacteria, opens a much 
needed new chapter in the treatment of 
primary hyperoxaluria.
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Specific molecular targeting 
of renal injury in obstructive 
nephropathy
RL Chevalier1
Progression of most renal disease involves tubulointerstitial injury, 
characterized by tubular atrophy, inflammatory cell infiltration, 
and interstitial fibrosis. Transforming growth factor-β1 is central in 
this process. As reported by Moon et al., molecular targeting of the 
transforming growth factor-β1 signaling pathway can markedly 
suppress renal injury resulting from unilateral ureteral obstruction, 
an established model of obstructive nephropathy. Specific kinase 
inhibitors are promising therapeutic agents to slow or attenuate 
progressive renal fibrosis.
Kidney International (2006) 70, 1200–1201. doi:10.1038/sj.ki.5001815
It has become increasingly apparent that 
renal interstitial fi brosis represents a fi nal 
common pathway for most forms of chron-
ically progressive renal disorders. Much 
attention has therefore focused on the cel-
lular and molecular mechanisms underly-
ing these disorders, with the ultimate aim 
of preventing or attenuating the progressive 
loss of renal parenchyma. Most progressive 
renal disease in adults is initiated by vascu-
lar and glomerular pathology (hyperten-
sion and diabetes), whereas in children, 
congenital renal maldevelopment pre-
dominates (with obstructive nephropathy 
comprising the greatest identifi able frac-
tion). Chronic unilateral ureteral obstruc-
tion (UUO) has emerged as a highly useful 
model for unraveling the intricacies of pro-
gressive renal interstitial fi brosis. Following 
UUO, renal tubular cell injury results from 
mechanical stretching, ischemia, hypoxia, 
or exposure to toxins such as oxygen free 
radicals, and the renal tubular epithelial 
cell either undergoes cell death by apop-
tosis or necrosis, or undergoes phenotypic 
transformation, acquiring mesenchymal 
characteristics1 (Figure 1). If the stimulus 
is transient, these changes can lead either 
to remodeling or to regeneration of the 
tubular epithelium. If the insult is severe or 
prolonged, however, a maladaptive 
response is activated, resulting in the 
attraction to the interstitium of infl am-
matory cells (particularly macrophages) 
that further damage the tubules and lead 
to increased deposition of extracellular 
matrix (Figure 1). Th us, three cell types 
appear to play vital roles in the progres-
sion of interstitial renal fi brosis: tubular 
epithelial cells, infi ltrating or proliferating 
infl ammatory cells, and interstitial fi brob-
lasts2 (Figure 1).
In the past decade, a variety of cell sig-
naling pathways have been elucidated, 
revealing overlapping regulation of cell 
death, inflammation, and fibrosis. The 
intrarenal renin-angiotensin system has 
emerged as a central player in this scheme, 
as angiotensin II modulates inflamma-
tion and cell death in addition to regulat-
ing interstitial fi brosis.3 For these reasons, 
angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers are 
increasing used clinically to slow or attenu-
ate the progression of renal disorders and 
proteinuria. Although angiotensin activates 
a broad spectrum of injurious cell signaling 
pathways, its stimulation of transforming 
growth factor beta (TGF-β1) appears to 
play a dominant role. Indeed, TGF-β1 has 
emerged as the quintessential fi brogenic 
cytokine that also acts as a proinfl amma-
tory and proapoptotic molecule (Figure 
1). Th us, administration of neutralizing 
TGF-β1 antibodies, or retrograde ureteral 
injection of fi broblasts containing anti-
sense oligodeoxynucleotides for TGF-β1, 
reduces progressive renal fi brosis result-
ing from UUO.2 Th e biology of TGF-β1 
signaling has been intensely investigated: 
it is now recognized that epithelial-
mesenchymal transition of tubular cells 
as well as the stimulation of extracellular 
matrix production are enhanced by the 
TGF-β1-regulated phosphorylation of 
Smad2 and Smad3. Smads are intracellu-
lar signalling proteins that participate in 
transcriptional activation of target genes. 
In contrast to Smad2 and Smad3, Smad7 
or hepatocyte growth factor have opposing 
actions and inhibit renal fi brosis induced 
by UUO.2
In this issue of Kidney International, 
Kim et al. have taken a novel approach 
by developing IN-1130, an inhibitor of 
activin receptor-like kinase (ALK) 5 that 
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